Astellas Q1 FY2027: Revenue jumps 27%, operating profit nearly doubles

Astellas’ consolidated Q1 results (full basis) showed revenue of ¥640.9 billion (up 26.7% YoY), operating profit of ¥184.5 billion (up 94.9%), and net income attributable to owners of the parent of ¥141.8 billion (up 107.3%).

Growth was fueled by continued global expansion of prostate cancer drug XTANDI, alongside strong contributions from strategic products PADCEV (urothelial cancer) and IZERVAY (age-related macular degeneration). Combined sales of these key products reached ¥160.3 billion, up 43.2% YoY. A significantly weaker yen, with an average rate of ¥159/USD (vs. ¥145 a year ago) and ¥185/EUR (vs. ¥164), boosted revenue by approximately ¥60 billion and operating profit by about ¥25.5 billion.

On a core basis, which the company uses to show underlying earnings power, core operating profit rose 55.6% to ¥221.4 billion, and core net profit increased 62.8% to ¥170.5 billion. Selling, general, and administrative expenses (up 9.2% YoY) and R&D costs (up 14.0%) grew, but gross profit rose 26.1%, driving margin improvement. Efficiency gains from Sustainable Margin Transformation (SMT) contributed about ¥3 billion each to SG&A and R&D savings.

Almost all of Astellas’ major products achieved solid growth. PADCEV expanded its global sales to ¥75.5 billion (+36.0%) on expanded first-line treatment indications and deeper penetration in bladder cancer. IZERVAY jumped 70.3% to ¥27.2 billion on rising new patient numbers and uptake among retinal specialists. VYLOY (gastric cancer) grew 50.7% to ¥21.1 billion, helped by wider diagnostic testing. VEOZAH (menopause-related symptoms) rose 54.8% to ¥14.9 billion, primarily in the US, and XOSPATA (leukemia) increased 27.3% to ¥21.6 billion. Top-selling XTANDI delivered stable 18.7% growth to ¥276.6 billion.

Regionally, the largest market, the US, generated ¥288.8 billion (+28.5%). International Markets (including Latin America, the Middle East, and Asia) surged 60.5% to ¥85.4 billion. Japan rose 15.5% to ¥79.6 billion, and Established Markets (Europe and others) grew 18.2% to ¥152.2 billion.

Total assets at the end of Q1 stood at ¥3,692.5 billion, up ¥125.5 billion from the previous fiscal year-end. Non-current assets were ¥2,206.9 billion (up ¥61.8 billion), and current assets ¥1,485.6 billion (up ¥63.7 billion). Cash and cash equivalents were ¥244.7 billion, down ¥36.9 billion, as strong operating cash flow of ¥86.5 billion was offset by outflows for intangible asset acquisitions and dividends.

Total equity increased by ¥113.6 billion to ¥1,944.4 billion, with the equity attributable to owners of the parent ratio at a stable 52.6%. Total liabilities rose ¥11.9 billion to ¥1,748.1 billion, including interest-bearing debt (bonds and borrowings) of ¥589.9 billion (+¥23.9 billion), mainly due to ¥30.0 billion in commercial paper issuance for short-term funding.

For shareholder returns, Astellas plans a ¥2 increase in the annual dividend to ¥80 per share (interim and year-end each ¥40), up from ¥78 in the previous year. No new share buybacks were announced, though small amounts were bought and sold during the quarter. Strong operating cash flow continues to support R&D investment and shareholder returns.

• Currency risk: The weak yen provided a substantial tailwind. A sharp yen appreciation, especially against the dollar given high US revenue exposure, could drag on results.
• Drug pricing and regulatory changes: Pricing pressures are intensifying in Japan and other markets, which could affect profitability of key products.
• Patent expirations and generics: XTANDI faces patent cliffs around 2030, exposing the portfolio to generic erosion. Building the next pipeline is critical.
• R&D uncertainty: Drug development success rates are low, and some strategic product candidates may fail clinically. R&D spending is rising, requiring careful cost-benefit management.
• M&A integration risk: Large deals carry integration expenses and goodwill impairment risk, demanding close capital efficiency monitoring.

Full-year FY2027 consolidated forecasts remain unchanged: revenue of ¥2,220.0 billion (+3.8% vs. prior year), operating profit of ¥395.0 billion (+3.2%), and net profit of ¥300.0 billion (+2.9%). Q1 progress reached 46.7% of the operating profit target, suggesting downside risks are limited. On a core basis, the company projects core operating profit of ¥620.0 billion (+11.6%) and core net profit of ¥460.0 billion (+8.4%).

(Figures in millions of yen; prior-year results are reference values from the financial statements.)

Exchange rate assumptions were not disclosed, but a weaker-than-expected yen would likely lift results, while additional R&D investment or drug price revisions pose downside risks.

A highlight of Q1 was the rapid expansion of the five strategic products (PADCEV, IZERVAY, VYLOY, VEOZAH, XOSPATA), which together generated ¥160.3 billion (+43.2% YoY), complementing XTANDI’s stable growth. PADCEV’s penetration in first-line and muscle-invasive bladder cancer settings pushed global sales to ¥75.5 billion, with further potential from broader approvals in Europe and emerging markets. IZERVAY is on track to become a blockbuster, with increasing adoption by retinal specialists and an annual sales run rate above ¥100 billion.

On the pipeline front, Astellas continues lifecycle management for these products while investing in next-generation modalities, including gene therapy and regenerative medicine. R&D expenditure in Q1 was ¥81.7 billion (+14.0% YoY), reflecting higher clinical development costs. With a limited time until key patent expirations, the medium-term priority is to establish the next revenue pillars—through internal development or strategic M&A—to sustain long-term growth.